argenx (NASDAQ:ARGX) Sets New 12-Month High - Should You Buy?

argenx SE (NASDAQ:ARGX - Get Free Report) shares hit a new 52-week high during trading on Monday . The stock traded as high as $646.35 and last traded at $645.95, with a volume of 175943 shares traded. The stock had previously closed at $621.29.

Analyst Ratings Changes

ARGX has been the topic of a number of recent analyst reports. JMP Securities lifted their price objective on argenx from $497.00 to $606.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. William Blair raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Friday, November 1st. Piper Sandler boosted their price objective on shares of argenx from $553.00 to $620.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. Wolfe Research raised argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price target for the company in a report on Tuesday, November 12th. Finally, Raymond James reiterated a "strong-buy" rating and issued a $605.00 price objective on shares of argenx in a research report on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $639.78.

argenx Stock Performance

The stock has a 50-day moving average of $607.17 and a 200 day moving average of $543.33. The firm has a market capitalization of $38.96 billion, a P/E ratio of -733.38 and a beta of 0.59.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the prior year, the firm earned ($1.25) EPS. On average, equities analysts predict that argenx SE will post 2.2 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Central Pacific Bank Trust Division acquired a new stake in argenx in the fourth quarter worth about $615,000. GAMMA Investing LLC lifted its stake in shares of argenx by 44.8% in the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company's stock valued at $155,000 after purchasing an additional 78 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of argenx in the 3rd quarter worth $88,339,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of argenx during the third quarter worth $652,000. Finally, Sanctuary Advisors LLC boosted its holdings in argenx by 17.5% during the third quarter. Sanctuary Advisors LLC now owns 2,064 shares of the company's stock worth $1,119,000 after buying an additional 308 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.